Evidence map›Paper›PMID 28191758›Full record

ArticleStem cells translational medicine2017

Preclinical Analysis of Fetal Human Mesencephalic Neural Progenitor Cell Lines: Characterization and Safety In Vitro and In Vivo.

Jisook Moon, Sigrid C Schwarz, Hyun-Seob Lee, Jun Mo Kang, Young-Eun Lee, Bona Kim, Mi-Young Sung, Günter Höglinger, Florian Wegner, Jin Su Kim and 5 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in Stem cells translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Blood-derived APLP1Science advances · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 3 countries.

Jisook MoonDepartment of Biotechnology, College of Life Science, CHA University, Seongnam-si, Gyeonggi-do, Korea.
Sigrid C SchwarzGerman Center for Neurodegenerative Diseases, Technical University Munich, Munich, Germany.
Hyun-Seob LeeGeneral Research Division, Korea Research-Driven Hospital, Bundang CHA Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea.
Jun Mo KangGeneral Research Division, Korea Research-Driven Hospital, Bundang CHA Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea.
Young-Eun LeeGeneral Research Division, Korea Research-Driven Hospital, Bundang CHA Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea.
Bona KimDevelopment Division, CHA Biotech, Seongnam-si, Gyeonggi-do, Korea.
Mi-Young SungDevelopment Division, CHA Biotech, Seongnam-si, Gyeonggi-do, Korea.
Günter HöglingerGerman Center for Neurodegenerative Diseases, Technical University Munich, Munich, Germany.
Florian WegnerDepartment of Neurology, Hannover Medical School, Hannover, Germany.
Jin Su KimMolecular Imaging Research Center, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Hyung-Min ChungDepartment of Stem Cell Biology, Graduate School of Medicine, Konkuk University, Gwangjin-gu, Seoul, Korea.
Sung Woon ChangDepartment of Obstetrics and Gynecology, CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea.
Kwang Yul ChaGeneral Research Division, Korea Research-Driven Hospital, Bundang CHA Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea.
Kwang-Soo KimMolecular Neurobiology Laboratory, Department of Psychiatry, Program in Neuroscience and Harvard Stem Cell Institute, McLean Hospital/Harvard Medical School, Belmont, Massachusetts, USA.
Johannes SchwarzGerman Center for Neurodegenerative Diseases, Technical University Munich, Munich, Germany.
CHA University · KRGerman Center for Neurodegenerative Diseases · DECHA University Bundang Medical Center · KRSTR Biotech (South Korea) · KRHarvard University · USKonkuk University · KRKorea Institute of Radiological and Medical Sciences · KRMedizinische Hochschule Hannover · DE

Funding

Protein-induced human iPS cells for personalized cell therapy of PDR01NS070577 · NINDS · MCLEAN HOSPITAL · PI KIM, KWANG-SOO, KORDOWER, JEFFREY H · 2010 to 2020
$4.9M
Functional Roles of Nurr1 for Midbrain Dopamine Neurons in Health and DiseaseR01NS084869 · NINDS · MCLEAN HOSPITAL · PI KIM, KWANG-SOO · 2014 to 2018
$1.7M
NINDS NIH HHS R01 NS070577NINDS NIH HHS R01 NS084869
6 · The paper itself

Abstract

We have developed a good manufacturing practice for long-term cultivation of fetal human midbrain-derived neural progenitor cells. The generation of human dopaminergic neurons may serve as a tool of either restorative cell therapies or cellular models, particularly as a reference for phenotyping region-specific human neural stem cell lines such as human embryonic stem cells and human inducible pluripotent stem cells. We cultivated 3 different midbrain neural progenitor lines at 10, 12, and 14 weeks of gestation for more than a year and characterized them in great detail, as well as in comparison with Lund mesencephalic cells. The whole cultivation process of tissue preparation, cultivation, and cryopreservation was developed using strict serum-free conditions and standardized operating protocols under clean-room conditions. Long-term-cultivated midbrain-derived neural progenitor cells retained stemness, midbrain fate specificity, and floorplate markers. The potential to differentiate into authentic A9-specific dopaminergic neurons was markedly elevated after prolonged expansion, resulting in large quantities of functional dopaminergic neurons without genetic modification. In restorative cell therapeutic approaches, midbrain-derived neural progenitor cells reversed impaired motor function in rodents, survived well, and did not exhibit tumor formation in immunodeficient nude mice in the short or long term (8 and 30 weeks, respectively). We conclude that midbrain-derived neural progenitor cells are a promising source for human dopaminergic neurons and suitable for long-term expansion under good manufacturing practice, thus opening the avenue for restorative clinical applications or robust cellular models such as high-content or high-throughput screening. Stem Cells Translational Medicine 2017;6:576-588.

Indexed as

Cell ProliferationNeurogenesisAnimalsBiomarkersCell Culture TechniquesCell LineDisease Models, AnimalDopaminergic NeuronsFemaleGestational AgeHumansMaleMesencephalonMice, Inbred BALB CMice, NudeMotor ActivityBiomarkersOxidopamineDopaminergic differentiationHuman fetal midbrain tissueNeural progenitor cellsParkinson's diseasePreclinical safetyRodentsTransplantation

Identifiers

PMID28191758
PMCPMC5442800
OpenAlexW2508124211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.